Granules India advances after USFDA completes inspection at Virginia facility

11 Dec 2017 Evaluate

Granules India is currently trading at Rs. 131.60, up by 4.55 points or 3.58% from its previous closing of Rs. 127.05 on the BSE.

The scrip opened at Rs. 130.10 and has touched a high and low of Rs. 134.00 and Rs. 129.00 respectively. So far 3,95,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 157.00 on 18-May-2017 and a 52 week low of Rs. 97.80 on 09-Jan-2017.

Last one week high and low of the scrip stood at Rs. 134.00 and Rs. 122.20 respectively. The current market cap of the company is Rs. 3,342.78 crore.

The promoters holding in the company stood at 48.18%, while Institutions and Non-Institutions held 21.43% and 30.40% respectively.

Granules India’s wholly-owned foreign subsidiary - Granules Pharmaceuticals, Inc. facility located in Chantilly, Virginia, USA has completed its first audit from December 4, 2017 to December 8, 2017 by the US Food and Drug Administration (USFDA) with one observation. Granules Pharmaceuticals, Inc. will respond to this observation within the stipulated time period.

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).


Granules India Share Price

593.90 -12.00 (-1.98%)
10-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1786.05
Dr. Reddys Lab 1354.20
Cipla 1470.05
Lupin 2190.50
Zydus Lifesciences 1004.05
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.